Tatva Chintan Pharma Chem Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6rx5p0ulayifuqufg8kreo9y.pdf

Key Takeaways


Demand Environment & Revenue Walk

Chintan Shah: "Based on the discussion & their forecast for calendar year 2024, also looking at a slowly improving business sentiments, we are now quite confident to state that next two quarters we will observe gradually improving business sentiments and expect shifting of gears from August onwards i.e Q2FY25."

SDA: The Growth Engine

Chintan Shah: "Our second largest customer is in China, who is yet to resume buying, who has not bought a single kg product since last one year."

PASC & New Capacity: The Margin Bridge

Chintan Shah: "if you look at the overhead increase that has happened in last nine months, periodically if you just compare it on a QoQ basis you will realize the steep rise in terms of your overhead costs and despite of that, at this topline, we are able to sustain is only the reason because we are seeing an artificial gain in terms of percentage margins on these products. Otherwise, we would definitely have been in trouble by now so far."

Electrolyte Salts & Emerging Businesses

Chintan Shah: "My key competitors in this area are the people who have large capacities to produce bromine, which is the key raw material for that. So, I believe product pricing is happening globally in a way where they are only getting rid of the bromine that they produce."

PTCs & Margin Resilience

Chintan Shah: "we continue to do that because that is our strategy and that is what we have presented to the customers that non Chinese origin raw material, absolutely indigenized, made in India and this is what a non-China supply chain is what we are offering and that is what has got them interested and we have got this opportunity with the large customer."

Guidance & Commitments

CommitmentSpecificsTimeline
FY24 revenue₹400-410 croreFY24 full year
FY24 EBITDA marginApproximately 20%FY24 full year
Q4FY24 revenue₹105-130 croreQ4FY24
Q4FY24 EBITDA margin20% to 23%Q4FY24
SDA fourth application validation resultResults from the large potential customer's fourth applicationBy end of March 2024
Photochlorination final approval shipmentOne container shipped for final customer approvalBy end of March 2024
Continuous flow pilot scale-upThree products scaled to pilot stageBy June 2024
SDA largest customer, first new product commercializationCommercial supplies beginJune/July quarter 2024
PASC agro products commercializationTwo products begin commercial suppliesAugust 2024
Electrolyte large customer automated lineFully automated battery production line goes online, demand increases drasticallyAugust 2024
Idle capacity resolutionPlant begins absorbing fixed costs as PASC production startsJuly/August 2024
SDA largest customer, second new product commercializationCommercial supplies beginOctober 2024
Electrolyte large European customerOnset of businessOctober 2024
New ₹70 crore agro intermediates plantCommercializationOctober 2024
PASC pharma final validationThree products formally validatedBy September 2024
PASC pharma commercial businessOnset of commercial suppliesBeginning of 2025
Photochlorination commercializationMoving toward commercial production2025
FY25 revenue growthAt least 70% growth, per an analyst's math that management called justifiableFY25
BS-7 SDA commercializationActual commercialization beginsFY26
Electrolyte customer demand scale-upDemand reaches 14-16X of current levels across four assembly linesOver next 3 years (2024-2026)
Incremental revenue over 3 years~₹680 crore total, with 60% from PASC (~₹200 crore) and 40% from SDA (~₹80-100 crore), per an analyst's mathOver next 3 years

Key Metrics

MetricQ3 FY24
Revenue from operations₹84.2 cr, degrowth of 30% YoY and 13% QoQ
EBITDA₹11 cr, decline of 39% YoY and 46% QoQ
EBITDA margin13.1%, vs 14.9% in Q3 FY23
PAT₹3.5 cr, degrowth of 70% YoY
PAT margin4.1%, vs 9.6% in Q3 FY23
Other income₹1.2 cr
Exports₹52.5 cr, 62% of revenue from operations
FY24 revenue guidance₹400–410 cr, with EBITDA at about 20% levels
PTCs segment revenue₹24.8 cr, growth of 7% QoQ, decline of 24% YoY
SDAs segment revenue₹32.3 cr, decline of 24% QoQ and 43% YoY
Pharma and Agro Intermediates and Speciality Chemicals revenue₹25.4 cr, decline of 12% QoQ and 4% YoY
Electrolyte Salts revenue₹1.2 cr, growth of 2% QoQ, degrowth of 71% YoY
Employee expense (9MFY24)14% of revenues, vs 9% in 9MFY23
CAPEX announced₹70 cr for one plant with 150 KL reactors and separate distillation plant, commercialization expected October 2024
Deferred revenue (containers postponed)~₹11.4 cr, 11 containers postponed from Q3 to Q4